Follow the Eikon Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). The latest transaction was filed on 8 September 2026 (Acquisition). Among the most active insiders: Column Group IV GP, LP. The full history is free.
7
Insider Decl.
n/a
Thresholds
€7m
4 ops.
Buy Volume
n/a
n/a
Sell Volume
49Σ signal
Buys €7mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
138,888 shares@ US$18.00100.0% of flowCommon StockSEC:0001193125-26-041544:0
Canonical exit: 5 May 2026 (T+90)
7 of 7 declarations
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a company focused on developing innovative therapies based on genome editing technology. It is listed on NASDAQ under the ticker symbol EIKN.